Finasteride in the treatment of men with androgenetic

Journal of the American Academy of Dermatology 39, 578-589

DOI: 10.1016/s0190-9622(98)70007-6

Citation Report

#	Article	IF	CITATIONS
2	Therapeutic Approach to Androgenetic Alopecia. Journal of Cutaneous Medicine and Surgery, 1999, 3, S3-21-S3-27.	0.6	1
3	Gender Differences in Hypertension in Spontaneously Hypertensive Rats. Hypertension, 1999, 34, 920-923.	1.3	181
4	The psychosocial consequences of androgenetic alopecia: a review of the research literature. British Journal of Dermatology, 1999, 141, 398-405.	1.4	183
5	Procyanidin Oligomers Selectively and Intensively Promote Proliferation of Mouse Hair Epithelial Cells In Vitro and Activate Hair Follicle Growth In Vivo11The authors disclosed conflict of interest Journal of Investigative Dermatology, 1999, 112, 310-316.	0.3	75
6	Management of androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology, 1999, 12, 205-214.	1.3	39
7	ANDROGEN METABOLISM AS IT AFFECTS HAIR GROWTH IN ANDROGENETIC ALOPECIA. Dermatologic Clinics, 1999, 17, 245-260.	1.0	5
8	Finasteride. Drugs and Therapy Perspectives, 1999, 13, 1-4.	0.3	0
9	Treatment of Hair Loss. New England Journal of Medicine, 1999, 341, 964-973.	13.9	410
10	Finasteride in the treatment of men with frontal male pattern hair loss. Journal of the American Academy of Dermatology, 1999, 40, 930-937.	0.6	208
11	The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology, 1999, 41, 550-554.	0.6	66
12	Clinical dose ranging studies with finasteride, a type 2 $5l^{\pm}$ -reductase inhibitor, in men with male pattern hair loss. Journal of the American Academy of Dermatology, 1999, 41, 555-563.	0.6	45
13	CHRONIC TREATMENT WITH FINASTERIDE DAILY DOES NOT AFFECT SPERMATOGENESIS OR SEMEN PRODUCTION IN YOUNG MEN. Journal of Urology, 1999, 162, 1295-1300.	0.2	114
14	Finasteride. Drugs, 1999, 57, 111-126.	4.9	146
15	Finasteride, a Type 2 5α-reductase inhibitor, in the treatment of men with androgenetic alopecia. Expert Opinion on Investigational Drugs, 1999, 8, 403-415.	1.9	43
16	The Biology of Hair Follicles. New England Journal of Medicine, 1999, 341, 491-497.	13.9	1,150
17	Androgenetic Alopecia: Overview. Journal of Cutaneous Medicine and Surgery, 1999, 3, S3-14-S3-20.	0.6	3
18	Male Pattern Baldness. Southern Medical Journal, 2000, 93, 657-662.	0.3	5
19	Recent advances: Dermatology. BMJ: British Medical Journal, 2000, 320, 850-853.	2.4	2

#	Article	IF	CITATIONS
21	Finasteride increases anagen hair in men with androgenetic alopecia. British Journal of Dermatology, 2000, 143, 804-810.	1.4	131
22	Medical management of male pattern hair loss. International Journal of Dermatology, 2000, 39, 585-586.	0.5	18
23	Male pattern hair loss: prevention rather than regrowth. International Journal of Dermatology, 2000, 39, 728-731.	0.5	6
24	LETTER TO THE EDITOR. Australasian Journal of Dermatology, 2000, 41, 55-55.	0.4	22
25	Investigation of topical application of procyanidin B-2 from apple to identify its potential use as a hair growing agent. Phytomedicine, 2000, 7, 529-536.	2.3	32
26	The Use of Finasteride in Treating Androgenetic Alopecia in Adult Men. Journal of Pharmacy Technology, 2000, 16, 50-53.	0.5	0
27	Dihydrotestosterone and the Concept of 5α–Reductase Inhibition in Human Benign Prostatic Hyperplasia. European Urology, 2000, 37, 367-380.	0.9	166
28	Role of Hormones in Pilosebaceous Unit Development. Endocrine Reviews, 2000, 21, 363-392.	8.9	348
29	Male Pattern Baldness and Coronary Heart Disease. Archives of Internal Medicine, 2000, 160, 165.	4.3	122
30	Systemic Therapy. , 2000, , 1747-1766.		1
31	Should men still go bald gracefully?. Lancet, The, 2000, 355, 161-162.	6.3	8
32	Finasteride and the hair cycle. Journal of the American Academy of Dermatology, 2000, 42, 848-849.	0.6	29
33	Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. Journal of the American Academy of Dermatology, 2000, 42, 1003-1007.	0.6	24
34	Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. Journal of the American Academy of Dermatology, 2000, 43, 768-776.	0.6	284
35	Hair disorders update: Alopecia to hirsutism. Current Problems in Dermatology, 2000, 12, 294-295.	0.1	0
37	Terapia della calvizie e dell'irsutismo con inibitori della 5α-riduttasi. L Endocrinologo, 2000, 1, 3-12.	0.0	0
38	Treatments for Androgenetic Alopecia and Alopecia Areata. Drugs, 2001, 61, 53-69.	4.9	68
39	The Value of Hair Cosmetics and Pharmaceuticals. Dermatology, 2001, 202, 275-282.	0.9	57

#	Article	IF	Citations
40	Hormonal effects on skin aging. Clinics in Geriatric Medicine, 2001, 17, 661-672.	1.0	56
41	Green tea: Biochemical and biological basis for health benefits. Vitamins and Hormones, 2001, 62, 1-94.	0.7	144
42	Social Perceptions of Male Pattern Baldness. A Review. Dermatology and Psychosomatics, 2001, 2, 63-71.	0.1	19
43	Female pattern hair loss. Journal of the American Academy of Dermatology, 2001, 45, S70-S80.	0.6	229
44	Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. Journal of the American Academy of Dermatology, 2001, 45, S81-S86.	0.6	125
45	5α-reductase inhibitors. Advances in Protein Chemistry, 2001, 56, 143-180.	4.4	5
46	The genetics of androgenetic alopecia. Clinics in Dermatology, 2001, 19, 149-154.	0.8	49
47	The psychology of hair loss and its implications for patient care. Clinics in Dermatology, 2001, 19, 161-166.	0.8	141
48	Androgenetic alopecia in men and women. Clinics in Dermatology, 2001, 19, 167-178.	0.8	84
50	Estado actual del uso de finasterida en el tratamiento de la alopecia androgenética. Piel, 2001, 16, 265-268.	0.0	5
51	Conducta a seguir ante un paciente con alopecia. FMC Formacion Medica Continuada En Atencion Primaria, 2001, 8, 113-127.	0.0	1
53	HORMONAL THERAPY IN DERMATOLOGY. Dermatologic Clinics, 2001, 19, 169-178.	1.0	18
54	Gender Differences in the Regulation of Blood Pressure. Hypertension, 2001, 37, 1199-1208.	1.3	986
55	Clinical application of $5\hat{l}$ ±-reductase inhibitors. Journal of Endocrinological Investigation, 2001, 24, 199-203.	1.8	51
56	Clinical use of 5α-reductase inhibitors. , 2001, , 571-596.		3
57	Evidence-Based Medicine for Dermatologic Surgeons. Dermatologic Surgery, 2001, 27, 511-514.	0.4	0
58	Evidence-Based Medicine for Dermatologic Surgeons: Concepts in Critical Appraisal of Information. Dermatologic Surgery, 2001, 27, 511-514.	0.4	7
59	Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology, 2001, 15, 418-421.	1.3	47

#	Article	IF	CITATIONS
60	Proliferating effect of extracts from woods and fungi on rat vibrissa dermal papilla cells. Journal of Wood Science, 2001, 47, 410-413.	0.9	2
61	5α-Reductase Inhibitors in the Treatment of Androgenetic Alopecia. International Journal of Cosmetic Surgery and Aesthetic Dermatology, 2001, 3, 107-119.	0.0	0
62	Testosterone levels in healthy men and the relation to behavioural and physical characteristics: facts and constructs. European Journal of Endocrinology, 2001, 144, 183-197.	1.9	210
63	Efficacy and Tolerability of Hairgain \hat{A}^{\otimes} in Individuals with Hair Loss: A Placebo-Controlled, Double-Blind Study. Journal of International Medical Research, 2001, 29, 2-6.	0.4	20
64	Production Rates of Dihydrotestosterone in Healthy Men and Women and in Men with Male Pattern Baldness: Determination by Stable Isotope/Dilution and Mass Spectrometry. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5762-5764.	1.8	24
65	Comparative Efficacy of Various Treatment Regimens for Androgenetic Alopecia in Men. Journal of Dermatology, 2002, 29, 489-498.	0.6	87
66	Unilateral Gynecomastia Induced by Treatment With $1\ \mathrm{mg}$ of Oral Finasteride. Archives of Dermatology, 2002, $138,543.$	1.7	28
68	Synthesis and Pharmacological Evaluation of New 16-Methyl Pregnane Derivatives Chemical and Pharmaceutical Bulletin, 2002, 50, 15-20.	0.6	18
69	Effects of Finasteride on Apoptosis and Regulation of the Human Hair Cycle. Journal of Cutaneous Medicine and Surgery, 2002, 6, 1-9.	0.6	23
70	The Potential Role of Minoxidil in the Hair Transplantation Setting. Dermatologic Surgery, 2002, 28, 894-900.	0.4	1
71	Hair Loss and Hirsutism in the Elderly. Clinics in Geriatric Medicine, 2002, 18, 121-133.	1.0	23
72	Acne. American Journal of Clinical Dermatology, 2002, 3, 571-578.	3.3	77
73	Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. Journal of the American Academy of Dermatology, 2002, 46, 517-523.	0.6	78
74	Female pattern hair loss. Journal of the American Academy of Dermatology, 2002, 47, 795.	0.6	38
75	Hair loss in women with hyperandrogenism: Four cases responding to finasteride. Journal of the American Academy of Dermatology, 2002, 47, 733-739.	0.6	102
76	Androgens and alopecia. Molecular and Cellular Endocrinology, 2002, 198, 89-95.	1.6	157
78	Structure–activity relationships for inhibition of human 5α-reductases by polyphenols. Biochemical Pharmacology, 2002, 63, 1165-1176.	2.0	190
79	Molecular mechanisms of androgenetic alopecia. Experimental Gerontology, 2002, 37, 981-990.	1.2	246

#	Article	IF	CITATIONS
81	Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia. World Journal of Urology, 2002, 19, 413-425.	1.2	119
82	Effects of Finasteride on Apoptosis and Regulation of the Human Hair Cycle. Journal of Cutaneous Medicine and Surgery, 2002, 6, 1-9.	0.6	24
83	Cutaneous Androgen Metabolism: Basic Research and Clinical Perspectives. Journal of Investigative Dermatology, 2002, 119, 992-1007.	0.3	211
84	The Potential Role of Minoxidil in the Hair Transplantation Setting. Dermatologic Surgery, 2002, 28, 894-900.	0.4	60
85	Hormonal treatment for male-pattern hair loss: implications for cancer of the prostate?. BJU International, 2002, 90, 682-685.	1.3	4
86	Molecular Genetic and Endocrine Mechanisms of Hair Growth. Hormone Research in Paediatrics, 2003, 60, 1-13.	0.8	50
89	Novel stilbenoids isolated from the heartwood of Shorea laeviforia. Journal of Wood Science, 2003, 49, 53-58.	0.9	22
90	Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia. Drug Development Research, 2003, 59, 292-306.	1.4	6
91	Implications of neuroimaging for the treatment of epilepsy. Annals of Neurology, 2003, 53, 286-288.	2.8	3
92	Progesterone, neurosteroids, and the hormonal basis of catamenial epilepsy. Annals of Neurology, 2003, 53, 288-291.	2.8	28
93	Treating psychogenic nonepileptic seizures: Easier said than done. Annals of Neurology, 2003, 53, 285-286.	2.8	10
94	Validation and clinical relevance of a novel scalp coverage scoring method. Skin Research and Technology, 2003, 9, 64-72.	0.8	10
95	Methods of evaluating hair growth. Australasian Journal of Dermatology, 2003, 44, 10-18.	0.4	74
96	Use of Finasteride in the Treatment of Men With Androgenetic Alopecia (Male Pattern Hair Loss). Journal of Investigative Dermatology Symposium Proceedings, 2003, 8, 20-23.	0.8	39
97	TrichoScan: A Novel Tool For The Analysis of Hair Growth In Vivo. Journal of Investigative Dermatology Symposium Proceedings, 2003, 8, 109-115.	0.8	70
98	Androgenetic Alopecia: Combining Medical and Surgical Treatments. Dermatologic Surgery, 2003, 29, 1130-1134.	0.4	21
99	Alopecia and its medical management. Facial Plastic Surgery Clinics of North America, 2003, 11, 267-276.	0.9	0
100	Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology, 2003, 62, 894-899.	0.5	50

#	ARTICLE	IF	CITATIONS
101	Hormonal status modifies renin-angiotensin system-regulating aminopeptidases and vasopressin-degrading activity in the hypothalamus-pituitary-adrenal axis of male mice. Life Sciences, 2003, 73, 525-538.	2.0	17
102	Production rates of testosterone and of dihydrotestosterone in female pattern hair loss. Metabolism: Clinical and Experimental, 2003, 52, 927-929.	1.5	16
103	Current and novel methods for assessing efficacy of hair growth promoters in pattern hair loss. Journal of the American Academy of Dermatology, 2003, 48, 253-262.	0.6	87
104	Transplants from balding and hairy androgenetic alopecia scalp regrow hair comparably well on immunodeficient mice. Journal of the American Academy of Dermatology, 2003, 48, 752-759.	0.6	19
105	The childbearing years: hair diseases. Clinics in Family Practice, 2003, 5, 709-732.	0.3	0
106	Androgenetic Alopecia. Dermatologic Surgery, 2003, 29, 1130-1134.	0.4	4
107	The 5alpha-reductase type 1, but not type 2, gene is expressed in anagen hairs plucked from the vertex area of the scalp of hirsute women and normal individuals. Brazilian Journal of Medical and Biological Research, 2003, 36, 1447-1454.	0.7	12
108	Evaluation of Sexual Function With an International Index of Erectile Function in Subjects Taking Finasteride for Androgenetic Alopecia. Archives of Dermatology, 2004, 140, 857-8.	1.7	47
109	Finasteride Treatment of Patterned Hair Loss in Normoandrogenic Postmenopausal Women. Dermatology, 2004, 209, 202-207.	0.9	79
110	Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2179-2184.	1.8	398
111	Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial. British Journal of Dermatology, 2004, 150, 341-345.	1.4	80
112	Follow-Up of 1 mg Finasteride Treatment of Male Pattern Baldness-Difference between Clinical Trials and Private Office Follow-Up: Influences on Prescribing Habits Evaluated. Dermatologic Surgery, 2004, 30, 761-763.	0.4	7
113	Androgen action on human skin - from basic research to clinical significance. Experimental Dermatology, 2004, 13, 5-10.	1.4	143
114	Clinical Case Notes. Retinoblastoma, microphthalmia and the chromosome 13q deletion syndrome. Clinical and Experimental Ophthalmology, 2004, 32, 101-103.	1.3	6
115	Clinical Case Notes. Malignant melanoma in eviscerated eyeball. Clinical and Experimental Ophthalmology, 2004, 32, 103-105.	1.3	7
116	Clinical Case Notes. Tamoxifen optic neuropathy. Clinical and Experimental Ophthalmology, 2004, 32, 105-106.	1.3	25
117	Clinical Case Notes. Propecia-associated bilateral cataract. Clinical and Experimental Ophthalmology, 2004, 32, 106-108.	1.3	12
118	Clinical Case Notes. Castleman's disease of the lacrimal gland. Clinical and Experimental Ophthalmology, 2004, 32, 108-110.	1.3	9

#	Article	IF	CITATIONS
119	Clinical Case Notes. Lipoid proteinosis: a rare disorder with pathognomonic lid lesions. Clinical and Experimental Ophthalmology, 2004, 32, 110-112.	1.3	12
120	Clinical Case Notes. Intraorbital ophthalmic artery aneurysms. Clinical and Experimental Ophthalmology, 2004, 32, 112-114.	1.3	20
121	Clinical Case Notes. Optical coherence tomography of adult-onset foveomacular vitelliform dystrophy. Clinical and Experimental Ophthalmology, 2004, 32, 114-118.	1.3	5
123	A Practitioner's Guide to Hair Loss Part 1—History, Biology, Genetics, Prevention, Conventional Treatments, and Herbals. Alternative and Complementary Therapies, 2004, 10, 135-143.	0.1	3
124	Ginecomastia unilateral secundaria al tratamiento con finasterida. Actas Dermo-sifiliográficas, 2004, 95, 199-200.	0.2	0
126	Pharmacologic management of pattern hair loss. Facial Plastic Surgery Clinics of North America, 2004, 12, 181-189.	0.9	15
127	Role of TGF-Î ² 2 in the human hair cycle. Journal of Dermatological Science, 2004, 35, 9-18.	1.0	184
128	An Open, Randomized, Comparative Study of Oral Finasteride and 5% Topical Minoxidil in Male Androgenetic Alopecia. Dermatology, 2004, 209, 117-125.	0.9	87
129	Finasteride in the treatment of alopecia. Expert Opinion on Pharmacotherapy, 2004, 5, 933-940.	0.9	70
130	Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men. Medical Hypotheses, 2004, 62, 112-115.	0.8	29
131	Follow-Up of 1 mg Finasteride Treatment of Male Pattern Baldness—Difference between Clinical Trials and Private Office Follow-Up. Dermatologic Surgery, 2004, 30, 761-763.	0.4	2
133	Polarized Light-Emitting Diode Magnification for Optimal Recipient Site Creation during Hair Transplant. Dermatologic Surgery, 2005, 31, 1124-1127.	0.4	5
134	Effects of Finasteride (1 mg) on Hair Transplant. Dermatologic Surgery, 2005, 31, 1268-1276.	0.4	29
135	Investigation of the topical application of procyanidin oligomers from apples to identify their potential use as a hair-growing agent. Journal of Cosmetic Dermatology, 2005, 4, 245-249.	0.8	29
136	Aging of hair. Journal of Cosmetic Dermatology, 2005, 4, 60-72.	0.8	97
137	Psychological aspects of hair disease. Journal of Cosmetic Dermatology, 2005, 4, 142-147.	0.8	24
138	Treatment of female pattern hair loss with oral antiandrogens. British Journal of Dermatology, 2005, 152, 466-473.	1.4	190
139	Adjusting O'Brien's Test to Control Type I Error for the Generalized Nonparametric Behrens-Fisher Problem. Biometrics, 2005, 61, 532-539.	0.8	48

#	Article	IF	Citations
143	Trichoscan: What Is New?. Dermatology, 2005, 211, 54-62.	0.9	36
144	Management of Hair Loss. Dermatologic Clinics, 2005, 23, 227-243.	1.0	77
145	Evaluation and treatment of male and female pattern hair loss. Journal of the American Academy of Dermatology, 2005, 52, 301-311.	0.6	227
146	Hair melanocytes as neuro-endocrine sensors—Pigments for our imagination. Molecular and Cellular Endocrinology, 2005, 243, 1-11.	1.6	44
147	Male androgenetic alopecia (Part II). The Journal of Men's Health & Gender: the Official Journal of the International Society for Men's Health & Gender, 2005, 2, 38-44.	0.3	7
148	Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men. Mayo Clinic Proceedings, 2005, 80, 1316-1322.	1.4	120
149	Antiandrogen therapy for androgenetic alopecia. Expert Review of Dermatology, 2006, 1, 261-269.	0.3	13
150	Antiandrogen Therapy for Skin and Hair Disease. Dermatologic Clinics, 2006, 24, 137-143.	1.0	20
151	Therapeutic strategies for treating hair loss. Drug Discovery Today: Therapeutic Strategies, 2006, 3, 101-110.	0.5	47
152	Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg) Tj ETQq $1\ 1\ 0.2$	784314 rg 0.6	BT/gverlock
153	The importance of dual 5α-reductase inhibition inÂtheÂtreatment of male pattern hair loss: ResultsÂofÂaÂrandomized placebo-controlled studyÂofÂdutasteride versus finasteride. Journal of the American Academy of Dermatology, 2006, 55, 1014-1023.	0.6	243
154	Tuchinda C, Srivannaboon S, Lim HW. Photoprotection by window glass, automobile glass, and sunglasses. J Am Acad Dermatol 2006;54:845-54 (May) Journal of the American Academy of Dermatology, 2006, 55, 74.	0.6	23
155	Medical Treatment of Noncicatricial Alopecia. Seminars in Cutaneous Medicine and Surgery, 2006, 25, 51-55.	1.6	22
159	Validation of scalp coverage scoring methods for scalp hair loss in male pattern hair loss (androgenetic alopecia). Skin Research and Technology, 2006, 12, 89-93.	0.8	6
160	Effects of Finasteride (1 mg) on Hair Transplant. Dermatologic Surgery, 2006, 31, 1268-1276.	0.4	31
161	Polarized Light-Emitting Diode Magnification for Optimal Recipient Site Creation during Hair Transplant. Dermatologic Surgery, 2006, 31, 1124-1127.	0.4	1
162	Hirsutism, postpartum telogen effluvium, and male pattern alopecia. Journal of Cosmetic Dermatology, 2006, 5, 81-86.	0.8	16
163	Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. British Journal of Dermatology, 2006, 154, 730-734.	1.4	27

#	Article	IF	CITATIONS
164	Enhancement of follicular delivery of finasteride by liposomes and niosomes. International Journal of Pharmaceutics, 2006, 323, 1-10.	2.6	121
165	Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese. European Journal of Clinical Pharmacology, 2006, 62, 939-946.	0.8	4
166	Natural Scalp Hair Regression in Preclinical Stages of Male Androgenetic Alopecia and Its Reversal by Finasteride. Skin Pharmacology and Physiology, 2006, 19, 168-176.	1.1	27
167	Nourkrin $\hat{A}^{\text{@}}$: Objective and Subjective Effects and Tolerability in Persons with Hair Loss. Journal of International Medical Research, 2006, 34, 514-519.	0.4	15
168	Finasteride Treatment of Female Pattern Hair Loss. Archives of Dermatology, 2006, 142, 298-302.	1.7	106
169	Inhibition of 5α-Reductase Activity in SZ95 Sebocytes and HaCaT Keratinocytes In Vitro. Hormone and Metabolic Research, 2007, 39, 141-148.	0.7	27
170	Hormonal regulation of hair follicles exhibits a biological paradox. Seminars in Cell and Developmental Biology, 2007, 18, 274-285.	2.3	96
171	A new classification of pattern hair loss that is universal for men and women: Basic and specific (BASP) classification. Journal of the American Academy of Dermatology, 2007, 57, 37-46.	0.6	127
172	A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology, 2007, 57, 767-774.	0.6	164
173	Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncology, The, 2007, 8 , 21-25.	5.1	99
174	Androgen Antagonists., 2007,, 1-3.		0
175	Dermatologic Manifestations of Polycystic Ovary Syndrome. American Journal of Clinical Dermatology, 2007, 8, 201-219.	3.3	75
176	Hair aging and anti-aging. Expert Review of Dermatology, 2007, 2, 607-617.	0.3	3
177	Androgenetic Alopecia. Endocrinology and Metabolism Clinics of North America, 2007, 36, 379-398.	1.2	129
178	Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecological Endocrinology, 2007, 23, 142-145.	0.7	48
179	Psychological Aspects of Cosmetic Surgery. , 0, , 182-198.		1
180	Effect of caffeine and testosterone on the proliferation of human hair folliclesinÂvitro. International Journal of Dermatology, 2007, 46, 27-35.	0.5	93
181	A woman with iatrogenic androgenetic alopecia responding to finasteride. British Journal of Dermatology, 2007, 156, 754-755.	1.4	14

#	Article	IF	CITATIONS
182	Immunohistochemical characterization of elastofibroma and exclusion of ABCC6 as a predisposing gene. British Journal of Dermatology, 2007, 156, 755-758.	1.4	8
183	Dutasteride improves male pattern hair loss in a randomized study in identical twins. Journal of Cosmetic Dermatology, 2007, 6, 9-13.	0.8	39
184	Exogen hair characterization in human scalp. Skin Research and Technology, 2007, 13, 436-443.	0.8	35
186	A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trials. Journal of Statistical Planning and Inference, 2008, 138, 321-335.	0.4	49
187	Androgens and hair growth. Dermatologic Therapy, 2008, 21, 314-328.	0.8	209
188	Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: better response in patients under 26Âyears old. British Journal of Dermatology, 2008, 158, 1121-1124.	1.4	21
189	Male pattern baldness: current treatments, future prospects. Drug Discovery Today, 2008, 13, 791-797.	3.2	44
190	5-Alpha Reductase Inhibitors and Erectile Dysfunction: The Connection. Journal of Sexual Medicine, 2008, 5, 2917-2924.	0.3	68
191	Advances in Hair Diseases. Advances in Dermatology, 2008, 24, 245-259.	2.0	4
192	Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology, 2008, 59, 547-566.	0.6	232
193	Hair and Scalp Diseases. , 0, , .		12
194	Photographic Imaging in Hair Loss. Basic and Clinical Dermatology, 2008, , 35-40.	0.1	O
195	Stem cell factor/c-Kit signalling in normal and androgenetic alopecia hair follicles. Journal of Endocrinology, 2008, 197, 11-23.	1.2	41
196	Female Pattern Hair Loss., 2008, , 171-186.		19
198	Finasteride-Induced Myalgia and HyperCKemia. Journal of Clinical Neuromuscular Disease, 2008, 10, 76-78.	0.3	10
199	Finasteride induced gynecomastia: Case report and review of the literature. International Journal of Trichology, 2009, 1, 27.	0.1	28
200	Hair evaluation methods: Merits and demerits. International Journal of Trichology, 2009, 1, 108.	0.1	95
201	Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: A randomized sequence, open-label, two-way crossover study. Clinical Therapeutics, 2009, 31, 2242-2248.	1.1	8

#	Article	IF	CITATIONS
202	Using global statistical tests in longâ€term Parkinson's disease clinical trials. Movement Disorders, 2009, 24, 1732-1739.	2.2	30
203	Roxithromycin antagonizes catagen induction in murine and human hair follicles: implication of topical roxithromycin as hair restoration reagent. Archives of Dermatological Research, 2009, 301, 347-355.	1.1	17
204	Genetik der androgenetischen Alopezie. Medizinische Genetik, 2009, 21, 511-518.	0.1	0
205	Fullerene nanomaterials potentiate hair growth. Nanomedicine: Nanotechnology, Biology, and Medicine, 2009, 5, 202-207.	1.7	33
206	Complications in Hair Restoration Surgery. Oral and Maxillofacial Surgery Clinics of North America, 2009, 21, 119-148.	0.4	25
207	Hair Loss in Women. Seminars in Cutaneous Medicine and Surgery, 2009, 28, 19-32.	1.6	92
208	The Biology of Hair Growth. , 2009, , 3-35.		10
209	Treatment strategies for alopecia. Expert Opinion on Pharmacotherapy, 2009, 10, 1017-1026.	0.9	36
210	The Male Patient in Aesthetic Medicine. , 2009, , .		12
211	Androgens and hair loss. Current Opinion in Endocrinology, Diabetes and Obesity, 2009, 16, 246-253.	1.2	50
212	Overactive bladder in men. , 2009, , 332-342.		1
214	Autologous Platelet-Rich Plasma: Guidelines in Plastic Surgery. Plastic and Reconstructive Surgery, 2010, 126, 269e-270e.	0.7	5
215	Prefabricated Cadaveric Osseous Flap Results in Viable Bone for Penile Autoaugmentation. Plastic and Reconstructive Surgery, 2010, 126, 266e-268e.	0.7	0
216	Repeated Bilateral Reduction Mammaplasty: A 12-Year Experience. Plastic and Reconstructive Surgery, 2010, 126, 263e-264e.	0.7	15
217	Mechanisms of Blepharoptosis following Cosmetic Glabellar Chemodenervation. Plastic and Reconstructive Surgery, 2010, 126, 248e-249e.	0.7	10
218	Pathophysiologic Changes in a Patient with Early-Onset Extensive Keloid Disease and a 20-Year Follow-Up. Plastic and Reconstructive Surgery, 2010, 126, 271e-274e.	0.7	0
219	Lateral Photography of the Nasal Tip: What Is Acceptable and Can It Be Improved?. Plastic and Reconstructive Surgery, 2010, 126, 250e-252e.	0.7	1
220	Lipofilling in Breast Cancer Patients: From Surgical Technique to Oncologic Point of View. Plastic and Reconstructive Surgery, 2010, 126, 262e-263e.	0.7	26

#	Article	IF	CITATIONS
221	Microsurgical Training Using a Pulsatile Membrane Pump and Chicken Thigh: A New, Realistic, Practical, Nonliving Educational Model. Plastic and Reconstructive Surgery, 2010, 126, 278e-279e.	0.7	21
222	A Simple and Effective Method for Phalloplasty in Female-to-Male Transsexuals. Plastic and Reconstructive Surgery, 2010, 126, 264e-265e.	0.7	10
223	Magnetic Resonance Imaging–Based Progress Control after Autologous Fat Transplantation. Plastic and Reconstructive Surgery, 2010, 126, 260e-261e.	0.7	11
224	Penile Epithesis: Preliminary Study. Plastic and Reconstructive Surgery, 2010, 126, 265e-266e.	0.7	13
225	Widespread Disregard of Photographic Documentation Standards in Plastic Surgery: A Brief Survey. Plastic and Reconstructive Surgery, 2010, 126, 274e-276e.	0.7	15
226	Broad-Vector Facial Suspension with a Zygomatic Arch Anchor for Paralyzed Face Revival. Plastic and Reconstructive Surgery, 2010, 126, 257e-258e.	0.7	0
227	The Ideal Donor-Site Dressing: Are We Clear Yet?. Plastic and Reconstructive Surgery, 2010, 126, 279e-280e.	0.7	2
228	The Plastic Surgeon's Role in Multispecialty Group Practice: A Recipe for Success and Longevity. Plastic and Reconstructive Surgery, 2010, 126, 276e-277e.	0.7	1
229	Clinical Trial Quality and Reporting Quality in American Society of Plastic Surgeons and German Conference Abstracts: A Transatlantic Perspective. Plastic and Reconstructive Surgery, 2010, 126, 281e-282e.	0.7	2
230	The Impact of the Medicare Sustainable Growth Rate Formula on Reconstructive Plastic Surgery. Plastic and Reconstructive Surgery, 2010, 126, 270e-271e.	0.7	9
231	A New Technique for Creating Spreader and Septal Extension Grafts. Plastic and Reconstructive Surgery, 2010, 126, 252e-254e.	0.7	2
232	Promotion effect ofÂnorgalanthamine, aÂcomponent ofÂCrinumÂasiaticum, onÂhair growth. European Journal of Dermatology, 2010, 20, 042-048.	0.3	21
233	Male androgenetic alopecia. Expert Opinion on Pharmacotherapy, 2010, 11, 1295-1304.	0.9	107
234	Male pattern baldness and prostate cancer risk in a population-based case–control study. Cancer Epidemiology, 2010, 34, 131-135.	0.8	30
235	Tratamiento de las alopecias. FMC Formacion Medica Continuada En Atencion Primaria, 2010, 17, 698-706.	0.0	0
236	Finasterideâ€induced depression: new insights into possible pathomechanisms. Journal of Cosmetic Dermatology, 2010, 9, 331-332.	0.8	22
237	Androgenetic alopecia in the paediatric population: a retrospective review of 57 patients. British Journal of Dermatology, 2010, 163, 378-385.	1.4	57
238	Effect of the dual 5αâ€reductase inhibitor, dutasteride, on serum testosterone and body mass index in men with benign prostatic hyperplasia. BJU International, 2010, 105, 970-974.	1.3	25

#	Article	IF	CITATIONS
240	Communicating Branch of Toe Web Veins as a Venous Return Pathway in Free Toe Pulp Flaps. Plastic and Reconstructive Surgery, 2010, 126, 268e-269e.	0.7	11
241	Treatment of Male Pattern Baldness with Botulinum Toxin: A Pilot Study. Plastic and Reconstructive Surgery, 2010, 126, 246e-248e.	0.7	48
242	Moral Hazard and Modern Health Care. Plastic and Reconstructive Surgery, 2010, 126, 280e-281e.	0.7	0
243	Breast Cerebrospinal Fluid after Ventriculoperitoneal Shunt Placement. Plastic and Reconstructive Surgery, 2010, 126, 261e-262e.	0.7	6
244	Resorbable Suture Fixation of Neonatal Mandibular Fractures: A Novel Technique. Plastic and Reconstructive Surgery, 2010, 126, 258e-260e.	0.7	3
245	Autoclave Sterilizable Pencils in Maxillofacial Surgery. Plastic and Reconstructive Surgery, 2010, 126, 255e-257e.	0.7	3
246	Visual Field Defect after Facial Rejuvenation with Botulinum Toxin Type A and Polyacrylamide Hydrogel Injection. Plastic and Reconstructive Surgery, 2010, 126, 249e-250e.	0.7	6
247	Tailoring Nasal Splints to Optimize Rhinoplasty Results. Plastic and Reconstructive Surgery, 2010, 126, 254e-255e.	0.7	0
248	Fascia Lata Harvesting: Minimal Access for Maximum Harvest. A New Technique. Plastic and Reconstructive Surgery, 2010, 126, 277e-278e.	0.7	16
250	Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. Journal of the American Academy of Dermatology, 2010, 63, 252-258.	0.6	96
251	Enhancement of percutaneous absorption of Finasteride by cosolvents, cosurfactant and surfactants. Pharmaceutical Development and Technology, 2010, 15, 619-625.	1.1	27
252	Comparative Gene Expression Profiling of Senescent and Androgenetic Alopecia Using Microarray Analysis., 2010,, 67-76.		5
253	Aging Hair., 2010,,.		22
254	Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia. Archives of Dermatology, 2010, 146, 1141-50.	1.7	168
256	Innovative Use of Spironolactone as an Antiandrogen in the Treatment of Female Pattern Hair Loss. Dermatologic Clinics, 2010, 28, 611-618.	1.0	60
257	A Rank-Based Test for Comparison of Multidimensional Outcomes. Journal of the American Statistical Association, 2010, 105, 578-587.	1.8	20
259	Finasteride-associated cataract and intraoperative floppy-iris syndrome. Journal of Cataract and Refractive Surgery, 2011, 37, 1351-1354.	0.7	36
260	Topical application of Polygonum multiflorum extract induces hair growth of resting hair follicles through upregulating Shh and \hat{l}^2 -catenin expression in C57BL/6 mice. Journal of Ethnopharmacology, 2011, 135, 369-375.	2.0	91

#	Article	IF	CITATIONS
261	Polymorphic CAG repeat numbers in the androgen receptor gene of female pattern hair loss patients. Journal of Dermatology, 2011, 38, 680-684.	0.6	11
262	Oral finasteride improved the quality of life of androgenetic alopecia patients. Journal of Dermatology, 2011, 38, 773-777.	0.6	27
263	A novel cosmetic approach to treat thinning hair. British Journal of Dermatology, 2011, 165, 24-30.	1.4	31
264	Delaying treatment in male-pattern hair loss affects the therapeutic response. Clinical and Experimental Dermatology, 2011, 36, 204-205.	0.6	3
265	Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up. Dermatologic Therapy, 2011, 24, 455-461.	0.8	57
266	Evidenceâ€based (S3) guideline for the treatment of androgenetic alopecia in women and in men. JDDG - Journal of the German Society of Dermatology, 2011, 9, S1-57.	0.4	215
267	Adverse Side Effects of $5\hat{l}$ ±-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients. Journal of Sexual Medicine, 2011, 8, 872-884.	0.3	220
268	Persistent Sexual Side Effects of Finasteride for Male Pattern Hair Loss. Journal of Sexual Medicine, 2011, 8, 1747-1753.	0.3	204
270	Steroid $5\hat{l}$ ±-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders. Current Pharmaceutical Design, 2011, 17, 151-167.	0.9	82
271	An overview of female pattern hair loss. Expert Review of Dermatology, 2011, 6, 317-327.	0.3	3
272	Inhibition of Inflammatory Gene Expression in Keratinocytes Using a Composition Containing Carnitine, Thioctic Acid and Saw Palmetto Extract. Evidence-based Complementary and Alternative Medicine, 2011, 2011, 1-7.	0.5	21
273	Effect of Dieckol, a Component of Ecklonia cava, on the Promotion of Hair Growth. International Journal of Molecular Sciences, 2012, 13, 6407-6423.	1.8	37
274	Topical Melatonin for Treatment of Androgenetic Alopecia. International Journal of Trichology, 2012, 4, 236.	0.1	47
275	Role of caffeine in the management of androgenetic alopecia. International Journal of Trichology, 2012, 4, 185.	0.1	12
276	Personalized Cancer Therapy for Urological Cancers: From Bench to Bedside and Back. Advances in Urology, 2012, 2012, 1-2.	0.6	0
277	Role of Platelet-rich Plasma in the Management of Androgenetic Alopecia. International Journal of Trichology, 2012, 4, 291.	0.1	11
278	The 5 Alpha-Reductase Isozyme Family: A Review of Basic Biology and Their Role in Human Diseases. Advances in Urology, 2012, 2012, 1-18.	0.6	225
279	Characteristics of Androgenetic Alopecia in Asian. Annals of Dermatology, 2012, 24, 243.	0.3	64

#	Article	IF	CITATIONS
280	Persistent Sexual Side Effects of Finasteride: Could They Be Permanent?. Journal of Sexual Medicine, 2012, 9, 2927-2932.	0.3	119
281	Global photographic assessment of men aged 18 to 60 years with male pattern hair loss receiving finasteride 1 mg or placebo. Journal of the American Academy of Dermatology, 2012, 67, 379-386.	0.6	39
282	Male alopecia, finasteride, and cancer risk. Community Oncology, 2012, 9, 65-66.	0.2	0
283	Medical Management Options for Hair Loss. , 2012, , 529-535.		O
284	Promotion effect of acankoreoside J, a lupane-triterpene in Acanthopanax koreanum, on hair growth. Archives of Pharmacal Research, 2012, 35, 1495-1503.	2.7	17
285	Aesthetic Medicine. , 2012, , .		9
286	Androgens and hair: a biological paradox with clinical consequences., 0,, 154-176.		11
287	Prostate cancer and androgenic alopecia. Expert Review of Endocrinology and Metabolism, 2012, 7, 169-173.	1.2	0
288	Improvement in scalp hair growth in androgenâ€deficient women treated with testosterone: a questionnaire study. British Journal of Dermatology, 2012, 166, 274-278.	1.4	24
289	Guidelines for the management of androgenetic alopecia (2010). Journal of Dermatology, 2012, 39, 113-120.	0.6	43
290	Evaluation of efficacy and safety of finasteride 1â€∫mg in 3177 Japanese men with androgenetic alopecia. Journal of Dermatology, 2012, 39, 27-32.	0.6	49
291	Combination therapy with finasteride and lowâ€dose dutasteride in the treatment of androgenetic alopecia. Australasian Journal of Dermatology, 2013, 54, 49-51.	0.4	20
292	In vivo hair growth-promoting efficacies of herbal extracts and their cubosomal suspensions. Journal of Industrial and Engineering Chemistry, 2013, 19, 1331-1339.	2.9	25
293	The prostamideâ€related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias. FASEB Journal, 2013, 27, 557-567.	0.2	56
294	Management of the Crown. Facial Plastic Surgery Clinics of North America, 2013, 21, 397-406.	0.9	2
295	Guidelines for management of androgenetic alopecia based on BASP classification–the Asian consensus committee guideline. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1026-1034.	1.3	35
296	Promotion effect of constituents from the root of Polygonum multiflorum on hair growth. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4801-4805.	1.0	53
297	Nonsurgical Therapy for Hair Loss. Facial Plastic Surgery Clinics of North America, 2013, 21, 335-342.	0.9	13

#	ARTICLE	IF	CITATIONS
298	Hair restoration approaches for early onset male androgenetic alopecia. Journal of Cosmetic Dermatology, 2013, 12, 223-231.	0.8	2
300	Neuroactive Steroid Levels are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology. Journal of Sexual Medicine, 2013, 10, 2598-2603.	0.3	84
301	Preventive Effects of Monascus on Androgen-Related Diseases: Androgenetic Alopecia, Benign Prostatic Hyperplasia, and Prostate Cancer. Journal of Agricultural and Food Chemistry, 2013, 61, 4379-4386.	2.4	15
302	Ascorbigen Induces Dermal Papilla Cell Proliferation <i>in Vitro</i> , but Fails to Modulate Chemotherapyâ€Induced Alopecia <i>in Vivo</i> . Phytotherapy Research, 2013, 27, 1863-1867.	2.8	2
303	Pattern Hair Loss in Men. Dermatologic Clinics, 2013, 31, 129-140.	1.0	64
304	Side Effects of 5â€Alpha Reductase Inhibitors: A Comprehensive Review. Sexual Medicine Reviews, 2013, 1, 24-41.	1.5	38
305	Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opinion on Drug Safety, 2013, 12, 81-90.	1.0	71
306	Female pattern alopecia: current perspectives. International Journal of Women's Health, 2013, 5, 541.	1.1	64
307	Age, What Age, How Old?. Anthropology (journal), 2013, 01, .	0.1	0
308	Cause of Androgenic Alopecia. Plastic and Reconstructive Surgery - Global Open, 2013, 1, e64.	0.3	21
309	Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. International Journal of Trichology, 2013, 5, 22.	0.1	47
311	Hair characteristics and androgenetic alopecia in Koreans. Journal of the Korean Medical Association, 2013, 56, 45.	0.1	11
312	The Promoting Effect of Ishige sinicola on Hair Growth. Marine Drugs, 2013, 11, 1783-1799.	2.2	25
313	Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of mixed etiology: a pilot study. Drug Design, Development and Therapy, 2013, 7, 413.	2.0	27
317	Effect of Pumpkin Seed Oil on Hair Growth in Men with Androgenetic Alopecia: A Randomized, Double-Blind, Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-7.	0.5	49
318	The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian Journal of Dermatology, Venereology and Leprology, 2014, 80, 521.	0.2	39
319	$5\hat{l}\pm$ -Reductase inhibitors in androgenetic alopecia. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 493-498.	1.2	31
320	A Review of Medical and Surgical Treatment Options for Androgenetic Alopecia. JAMA Facial Plastic Surgery, 2014, 16, 444-450.	2.2	42

#	Article	IF	CITATIONS
321	Platelet-rich plasma in androgenic alopecia: Myth or an effective tool. Journal of Cutaneous and Aesthetic Surgery, 2014, 7, 107.	0.2	122
322	Efficacy and Safety of a Low-level Laser Device in the Treatment of Male and Female Pattern Hair Loss: A Multicenter, Randomized, Sham Device-controlled, Double-blind Study. American Journal of Clinical Dermatology, 2014, 15, 115-127.	3.3	167
323	Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis. Journal of Dermatology, 2014, 41, 285-291.	0.6	44
324	Impact of Alpha Blockers, 5-alpha Reductase Inhibitors and Combination Therapy on Sexual Function. Current Urology Reports, 2014, 15, 441.	1.0	12
325	Organic Causes of Erectile Dysfunction in Men Under 40. Urologia Internationalis, 2014, 92, 1-6.	0.6	1,494
326	The Dermal Papilla: An Instructive Niche for Epithelial Stem and Progenitor Cells in Development and Regeneration of the Hair Follicle. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015180-a015180.	2.9	153
327	"Cold―X5 Hairlaserâ,,¢ used to treat male androgenic alopecia and hair growth: an uncontrolled pilot study. BMC Research Notes, 2014, 7, 103.	0.6	17
328	Common Dermatologic Conditions. Medical Clinics of North America, 2014, 98, 445-485.	1.1	13
329	Effect of dutasteride 0.5Âmg/d in men with androgenetic alopecia recalcitrant to finasteride. International Journal of Dermatology, 2014, 53, 1351-1357.	0.5	43
331	Hair transplantation in burn scar alopecia. Scars, Burns & Healing, 2015, 1, 205951311560776.	0.6	13
332	Safety concerns regarding $5l_{\pm}$ reductase inhibitors for the treatment of androgenetic alopecia. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 248-253.	1.2	33
333	Enhancing hair follicle regeneration by nonablative fractional laser: Assessment of irradiation parameters and tissue response. Lasers in Surgery and Medicine, 2015, 47, 331-341.	1.1	20
334	A Fast and Efficient <scp>UPLCâ€ESIâ€MS</scp> / <scp>MS</scp> Method for Detection, Identification, and Quantitative Analysis of Bioactive Substances in Medicinal Herbal Extracts of Preventing Hair Loss. Bulletin of the Korean Chemical Society, 2015, 36, 2469-2476.	1.0	4
335	Autologous Platelet Rich Plasma as a Treatment of Male Androgenetic Alopecia: Study of 14 Cases. Journal of Clinical & Experimental Dermatology Research, 2015, 06, .	0.1	5
336	Female Pattern Hair Loss: a clinical and pathophysiological review. Anais Brasileiros De Dermatologia, 2015, 90, 529-543.	0.5	113
337	Hair restoration surgery: challenges and solutions. Clinical, Cosmetic and Investigational Dermatology, 2015, 8, 361.	0.8	38
338	The Success of Thread-embedding Therapy in Generating Hair Re-growth in Mice Points to Its Possibly Having a Similar Effect in Humans. Journal of Pharmacopuncture, 2015, 18, 20-25.	0.4	23
339	An Update on Hair Restoration. Journal of Aesthetic & Reconstructive Surgery, 2015, 01, .	0.1	1

#	Article	IF	CITATIONS
340	Selbstzahlerleistungen in der Dermatologie und der Ästhetischen Medizin. , 2015, , .		7
341	Topical minoxidil fortified with finasteride: An account of maintenance of hair density after replacing oral finasteride. Indian Dermatology Online Journal, 2015, 6, 17.	0.2	47
342	Adverse effects of common medications on male fertility. Nature Reviews Urology, 2015, 12, 401-413.	1.9	91
343	Fiveâ€year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. Journal of Dermatology, 2015, 42, 735-738.	0.6	19
344	Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia. JAMA Dermatology, 2015, 151, 600.	2.0	53
345	Association of male pattern baldness with angiographic coronary artery disease severity and collateral development. Netherlands Heart Journal, 2015, 23, 265-274.	0.3	11
346	A Two-Stepped Culture Method for Efficient Production of Trichogenic Keratinocytes. Tissue Engineering - Part C: Methods, 2015, 21, 1070-1079.	1.1	25
347	Androgenetic, Diffuse and Senescent Alopecia in Men: Practical Evaluation and Management. Current Problems in Dermatology, 2015, 47, 33-44.	0.8	12
348	Normal and Aging Hair Biology and Structure i¿½Aging and Hair'. Current Problems in Dermatology, 2015, 47, 1-9.	0.8	20
349	A New Topical Formulation of Minoxidil and Finasteride Improves Hair Growth in Men with Androgenetic Alopecia. Journal of Clinical & Experimental Dermatology Research, 2015, 06, .	0.1	5
350	Randomized Questionnaire Based Case–Control Research Study on Evaluation of Sexual Function in Indian Patients Taking Oral Finasteride for Androgenetic Alopecia. Dermatology and Therapy, 2015, 5, 231-234.	1.4	11
351	The Difficult Dermatologic Condition. , 2015, , 49-137.		1
352	Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 177-198.	2.6	90
354	Age-related hair changes in men: Mechanisms and management of alopecia and graying. Maturitas, 2015, 80, 58-62.	1.0	39
355	Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. Journal of Steroid Biochemistry and Molecular Biology, 2015, 146, 74-79.	1.2	69
356	Persistent Sexual, Emotional, and Cognitive Impairment Post-Finasteride. American Journal of Men's Health, 2015, 9, 222-228.	0.7	88
357	Acceleration of Hair Growth Rate by Topical Liposomal Cepharanthine in Male Androgenetic Alopecia. Hair Therapy & Transplantation, 2016, 06, .	0.0	1
358	Beyond testosterone cypionate: evidence behind the use of nandrolone in male health and wellness. Translational Andrology and Urology, 2016, 5, 213-219.	0.6	14

#	ARTICLE	IF	CITATIONS
359	Cornu cervi pantotrichum Pharmacopuncture Solution Facilitate Hair Growth in C57BL/6 Mice. Journal of Pharmacopuncture, 2016, 19, 122-128.	0.4	5
360	Safety and Tolerability of the Dual 5-Alpha Reductase Inhibitor Dutasteride in the Treatment of Androgenetic Alopecia. Annals of Dermatology, 2016, 28, 444.	0.3	23
361	Treatment of male androgenetic alopecia with topical products containing <scp><i>S</i></scp> <i>erenoa repens</i> extract. Australasian Journal of Dermatology, 2016, 57, e76-82.	0.4	22
362	Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and Their Receptors in the Male Rat Brain. Neuroendocrinology, 2016, 103, 746-757.	1.2	39
363	Testosterone Deficiency and the Prostate. Urologic Clinics of North America, 2016, 43, 203-208.	0.8	9
364	Effect of $5\hat{l}_{\pm}$ -Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials. Journal of Sexual Medicine, 2016, 13, 1297-1310.	0.3	58
365	Sexual Side Effects of Medical and Surgical Benign Prostatic Hyperplasia Treatments. Urologic Clinics of North America, 2016, 43, 393-404.	0.8	12
366	Androgenetic Alopecia: An Update of Treatment Options. Drugs, 2016, 76, 1349-1364.	4.9	153
367	Perception of Hair Transplant for Androgenetic Alopecia. JAMA Facial Plastic Surgery, 2016, 18, 413-418.	2.2	30
368	Promotion Effect of Apo-9′-fucoxanthinone from <i>Sargassum muticum</i> on Hair Growth <i>via</i> the Activation of Wnt/β-Catenin and VEGF-R2. Biological and Pharmaceutical Bulletin, 2016, 39, 1273-1283.	0.6	20
369	Persistent Sexual Dysfunction with Finasteride 1Âmg Taken for Hair Loss. Pharmacotherapy, 2016, 36, 1180-1184.	1.2	22
370	Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens. Psychoneuroendocrinology, 2016, 74, 387-396.	1.3	14
371	Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ, The, 2016, 354, i4823.	3.0	29
372	Photographic Assessment of Change in Trichotillomania: Psychometric Properties and Variables Influencing Interpretation. Journal of Psychopathology and Behavioral Assessment, 2016, 38, 505-513.	0.7	2
373	Trattamenti e cosmetici anticaduta. EMC - Cosmetologia Medica E Medicina Degli Inestetismi Cutanei, 2016, 13, 1-13.	0.0	0
375	Bayesian multiple imputation for missing multivariate longitudinal data from a Parkinson's disease clinical trial. Statistical Methods in Medical Research, 2016, 25, 821-837.	0.7	12
376	Analysis of the Maillard reaction in human hair using Fourier transform infrared spectroscopic imaging and a focal-plane array detector. Analytical and Bioanalytical Chemistry, 2016, 408, 2363-2372.	1.9	3
377	Hair growth effect of traditional Chinese medicine BeauTop on androgenetic alopecia patients: A randomized double-blind placebo-controlled clinical trial. Experimental and Therapeutic Medicine, 2017, 13, 194-202.	0.8	5

#	Article	IF	CITATIONS
378	Platelet rich plasma for treatment of non-scarring hair loss: systematic review of literature. Journal of Dermatological Treatment, 2017, 28, 574-581.	1.1	26
379	Neuroactive steroid levels and psychiatric and andrological features in post-finasteride patients. Journal of Steroid Biochemistry and Molecular Biology, 2017, 171, 229-235.	1.2	67
380	A Critical Assessment of the Evidence for Low-Level Laser Therapy in the Treatment of Hair Loss. Dermatologic Surgery, 2017, 43, 188-197.	0.4	34
381	Hair Physiology (Hair Growth, Alopecia, Scalp Treatment, etc.). , 2017, , 767-780.		1
382	Assessing finasterideâ€associated sexual dysfunction using the <scp>FAERS</scp> database. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1069-1075.	1.3	27
383	Industrial-scale processing of activated platelet-rich plasma from specific pathogen-free pigs and its effect on promoting human hair follicle dermal papilla cell cultivation. Journal of the Taiwan Institute of Chemical Engineers, 2017, 71, 28-37.	2.7	8
384	Circulating and intraprostatic sex steroid hormonal profiles in relation to male pattern baldness and chest hair density among men diagnosed with localized prostate cancers. Prostate, 2017, 77, 1573-1582.	1.2	8
385	Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: possible mechanism via VEGF induction. Archives of Dermatological Research, 2017, 309, 729-738.	1.1	31
386	Erectile Dysfunction in Young Menâ€"A Review of the Prevalence and Risk Factors. Sexual Medicine Reviews, 2017, 5, 508-520.	1.5	198
387	Topically used herbal products for the treatment of hair loss: preclinical and clinical studies. Archives of Dermatological Research, 2017, 309, 595-610.	1.1	25
390	An Asian traditional herbal complex containing Houttuynia cordata Thunb, Perilla frutescens Var. acuta and green tea stimulates hair growth in mice. BMC Complementary and Alternative Medicine, 2017, 17, 515.	3.7	13
391	Bioactives in Chinese Proprietary Medicine Modulates 5α-Reductase Activity and Gene Expression Associated with Androgenetic Alopecia. Frontiers in Pharmacology, 2017, 8, 194.	1.6	8
392	Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cytokine Concentrations Obtained by Different Collection Systems. International Journal of Molecular Sciences, 2017, 18, 408.	1.8	141
393	Undariopsis peterseniana Promotes Hair Growth by the Activation of Wnt/ \hat{l}^2 -Catenin and ERK Pathways. Marine Drugs, 2017, 15, 130.	2.2	30
394	Hair Regenerative Mechanisms of Red Ginseng Oil and Its Major Components in the Testosterone-Induced Delay of Anagen Entry in C57BL/6 Mice. Molecules, 2017, 22, 1505.	1.7	39
395	Gold thread implantation promotes hair growth in human and mice. Laboratory Animal Research, 2017, 33, 291.	1.1	5
396	Androgenic Alopecia: Cross-Talk Between Cell Signal Transduction Pathways. , 2017, , .		1
397	Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss. Dermatologic Therapy, 2018, 31, e12588.	0.8	15

#	Article	IF	CITATIONS
398	Post-finasteride syndrome and post-SSRI sexual dysfunction: two sides of the same coin?. Endocrine, 2018, 61, 180-193.	1.1	48
399	Stability Study of Finasteride: Stability-Indicating LC Method, In Silico and LC–ESI-MS Analysis of Major Degradation Product, and an In Vitro Biological Safety Study. Journal of Chromatographic Science, 2018, 56, 531-540.	0.7	1
400	Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. Journal of Visualized Experiments, 2018 , , .	0.2	30
401	Research Brief: Self-Reports of a Constellation of Persistent Antiandrogenic, Estrogenic, Physical, and Psychological Effects of Finasteride Usage Among Men. American Journal of Men's Health, 2018, 12, 900-906.	0.7	13
402	Sesquiterpene-Enriched Extract of <i>Curcuma aeruginosa</i> Roxb. Retards Axillary Hair Growth: A Randomised, Placebo-Controlled, Double-Blind Study. Skin Pharmacology and Physiology, 2018, 31, 99-106.	1.1	4
403	Understanding and Addressing Hair Disorders in Transgender Individuals. American Journal of Clinical Dermatology, 2018, 19, 517-527.	3.3	35
404	Low-level laser therapy for the treatment of androgenic alopecia: a review. Lasers in Medical Science, 2018, 33, 425-434.	1.0	55
405	A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. Medical Hypotheses, 2018, 111, 73-81.	0.8	41
406	Systematic review of low-level laser therapy for adult androgenic alopecia. Journal of Cosmetic and Laser Therapy, 2018, 20, 229-236.	0.3	15
407	Systemic Therapies for Scarring and Non-scarring Alopecia. , 2018, , 495-515.		1
408	Drug Treatment for Androgenetic Alopecia: First Italian Questionnaire Survey on What Dermatologists Think about Finasteride. Dermatology and Therapy, 2018, 8, 259-267.	1.4	9
409	Synergistic effect of platelet-rich plasma injections and scalp lifting in androgenetic alopecia. Clinics in Dermatology, 2018, 36, 673-679.	0.8	5
410	Annurca Apple Nutraceutical Formulation Enhances Keratin Expression in a Human Model of Skin and Promotes Hair Growth and Tropism in a Randomized Clinical Trial. Journal of Medicinal Food, 2018, 21, 90-103.	0.8	26
411	Germacrone and sesquiterpene-enriched extracts fromÂCurcuma aeruginosa Roxb. increase skin penetration of minoxidil, a hair growth promoter. Drug Delivery and Translational Research, 2018, 8, 140-149.	3.0	17
412	Evidenceâ€based (S3) guideline for the treatment of androgenetic alopecia in women and in men – short version. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 11-22.	1.3	191
413	Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. Journal of Cosmetic and Laser Therapy, 2018, 20, 252-257.	0.3	9
414	Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. Medical Science Monitor, 2018, 24, 7770-7777.	0.5	14
415	Medical Treatment of Alopecia. , 2018, , .		0

#	Article	IF	Citations
416	Seaweeds as Source of Bioactive Substances and Skin Care Therapy—Cosmeceuticals, Algotheraphy, and Thalassotherapy. Cosmetics, 2018, 5, 68.	1.5	168
417	Optimal Weighted Wilcoxon–Mann–Whitney Test for Prioritized Outcomes. ICSA Book Series in Statistics, 2018, , 3-40.	0.0	1
418	Hair-Growth Potential of Ginseng and Its Major Metabolites: A Review on Its Molecular Mechanisms. International Journal of Molecular Sciences, 2018, 19, 2703.	1.8	71
419	Mackerel-Derived Fermented Fish Oil Promotes Hair Growth by Anagen-Stimulating Pathways. International Journal of Molecular Sciences, 2018, 19, 2770.	1.8	18
420	Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. Acta Dermato-Venereologica, 2018, 99, 12-17.	0.6	21
421	Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial. Dermatologic Surgery, 2018, 44, 1411-1420.	0.4	40
422	A bald statement â€" Current approaches to manipulate miniaturisation focus only on promoting hair growth. Experimental Dermatology, 2018, 27, 959-965.	1.4	31
423	Efficacy of nonâ€surgical treatments for androgenetic alopecia: a systematic review and network metaâ€analysis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2112-2125.	1.3	68
424	LLLT: Does It Work?., 2018,, 653-657.		0
425	A randomized, doubleâ€blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2257-2263.	1.3	64
426	The Post-finasteride Syndrome: Clinical Manifestation of Drug-Induced Epigenetics Due to Endocrine Disruption. Current Sexual Health Reports, 2018, 10, 88-103.	0.4	9
427	Medications With Male Reproductive Side Effects. , 2018, , 207-216.		0
428	Evaluating the Efficacy of Different Platelet-Rich Plasma Regimens for Management of Androgenetic Alopecia: A Single-Center, Blinded, Randomized Clinical Trial. Dermatologic Surgery, 2018, 44, 1191-1200.	0.4	53
429	Guidelines for the diagnosis and treatment of maleâ€pattern and femaleâ€pattern hair loss, 2017 version. Journal of Dermatology, 2018, 45, 1031-1043.	0.6	50
431	The Impact of 5α-Reductase Inhibitor Use for Male Pattern Hair Loss on Men's Health. Current Urology Reports, 2018, 19, 65.	1.0	18
432	Clinical Trials and Hair Loss. , 2019, , 267-284.		1
433	Androgenetic Alopecia. , 2019, , 67-81.		2
434	Development of finasteride polymer microspheres for systemic application in androgenic alopecia. International Journal of Molecular Medicine, 2019, 43, 2409-2419.	1.8	12

#	Article	IF	CITATIONS
435	A Systematic Review of Outcomes and Patient Satisfaction Following Surgical and Non-surgical Treatments for Hair Loss. Aesthetic Plastic Surgery, 2019, 43, 1523-1535.	0.5	8
436	Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia. PLoS ONE, 2019, 14, e0222533.	1.1	4
437	Influence of Postoperative Finasteride Therapy on Recurrence of Gynecomastia After Mastectomy in Men Taking Finasteride for Alopecia. American Journal of Men's Health, 2019, 13, 155798831987142.	0.7	3
438	Hair Growth Promoting Effect of <i>Hottuynia cordata</i> Extract in Cultured Human Hair Follicle Dermal Papilla Cells. Biological and Pharmaceutical Bulletin, 2019, 42, 1665-1673.	0.6	19
439	Self-Assessments of Standardized Scalp Massages for Androgenic Alopecia: Survey Results. Dermatology and Therapy, 2019, 9, 167-178.	1.4	5
440	Progressive expression of PPARGC1 \hat{i}_{\pm} is associated with hair miniaturization in androgenetic alopecia. Scientific Reports, 2019, 9, 8771.	1.6	13
441	Sexual dysfunction in men taking systemic dermatologic medication: A systematic review. Journal of the American Academy of Dermatology, 2019, 81, 163-172.	0.6	13
442	Maintenance of optimised hair growth from viable terminal scalp hair follicles at baseline with oral finasteride in male pattern hair loss and first evidence of a "drug dependencyâ€and a postâ€finasteride "rebound effect†Skin Research and Technology, 2019, 25, 712-719.	0.8	4
443	Hair Loss in Men and Women. Advances in Cosmetic Surgery, 2019, 2, 161-176.	0.4	0
444	In Silico Drug Design Methods for Drug Repurposing. , 2019, , 47-84.		10
445	Finasteride for androgenetic alopecia is not associated with sexual dysfunction: a surveyâ€based, singleâ€centre, controlled study. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1393-1397.	1.3	18
446	The Mossman–Pacey Paradox. Journal of Internal Medicine, 2019, 286, 233-234.	2.7	3
447	Post-Finasteride Syndrome: An Induced Delusional Disorder with the Potential of a Mass Psychogenic Illness?. Skin Appendage Disorders, 2019, 5, 320-326.	0.5	19
448	Alopecia and techniques in hair restoration: an overview for the cosmetic surgeon. Oral and Maxillofacial Surgery, 2019, 23, 123-131.	0.6	6
449	SNP variation in male pattern hair loss in Russians with different dihydrotestosterone levels. Meta Gene, 2019, 19, 219-224.	0.3	3
451	Evaluation of longâ€term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. Journal of Dermatology, 2019, 46, 139-143.	0.6	23
453	The rise of transcutaneous drug delivery for the management of alopecia: a review of existing literature and an eye towards the future. Journal of Cosmetic and Laser Therapy, 2019, 21, 247-254.	0.3	10
454	Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. Sexual Medicine Reviews, 2019, 7, 277-282.	1.5	24

#	Article	IF	CITATIONS
455	Finasteride and androgenic alopecia; from therapeutic options to medical implications. Journal of Dermatological Treatment, 2020, 31, 415-421.	1.1	22
456	Primary and Preventative Care for Transgender Patients. , 2020, , 114-130.		1
457	Post-finasteride syndrome: An emerging clinical problem. Neurobiology of Stress, 2020, 12, 100209.	1.9	49
458	Topical ketoconazole for the treatment of androgenetic alopecia: A systematic review. Dermatologic Therapy, 2020, 33, e13202.	0.8	16
461	Is there a role for 5αâ€reductase inhibitors in transgender individuals?. Andrology, 2020, 9, 1729-1731.	1.9	11
462	A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia. Stem Cells Translational Medicine, 2020, 9, 839-849.	1.6	45
463	Functional complexity of hair follicle stem cell niche and therapeutic targeting of niche dysfunction for hair regeneration. Journal of Biomedical Science, 2020, 27, 43.	2.6	73
464	Low-level laser therapy and narrative review of other treatment modalities in androgenetic alopecia. Lasers in Medical Science, 2020, 35, 1239-1244.	1.0	10
465	A review of the treatment of male pattern hair loss. Expert Opinion on Pharmacotherapy, 2020, 21, 603-612.	0.9	83
466	Protective Role of Nutritional Plants Containing Flavonoids in Hair Follicle Disruption: A Review. International Journal of Molecular Sciences, 2020, 21, 523.	1.8	25
467	Integral characterization of normal and alopecic hair at different degeneration stages by in-situ visible and chemical imaging. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2020, 235, 118315.	2.0	7
468	Efficacy of non-surgical treatments for androgenetic alopecia in men and women: a systematic review with network meta-analyses, and an assessment of evidence quality. Journal of Dermatological Treatment, 2022, 33, 62-72.	1.1	24
469	QR 678 & QR678 Neo Vs PRP—A randomised, comparative, prospective study. Journal of Cosmetic Dermatology, 2020, 19, 2877-2885.	0.8	14
470	Untargeted Metabolomics and Steroid Signatures in Urine of Male Pattern Baldness Patients after Finasteride Treatment for a Year. Metabolites, 2020, 10, 131.	1.3	8
471	Usefulness of homeâ€use microneedle devices in the treatment of pattern hair loss. Journal of Cosmetic Dermatology, 2021, 20, 591-596.	0.8	10
472	Antiandrogens and Androgen Inhibitors. , 2021, , 366-381.e5.		0
473	Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opinion on Pharmacotherapy, 2021, 22, 179-189.	0.9	18
474	The Use of Medicinal Plants for the Treatment of Alopecia in the Canon of Avicenna: An Evidence-Based Review. Advances in Experimental Medicine and Biology, 2021, 1308, 291-308.	0.8	1

#	Article	IF	Citations
475	A Multimodal Hair-Loss Treatment Strategy Using a New Topical Phytoactive Formulation: A Report of Five Cases. Case Reports in Dermatological Medicine, 2021, 2021, 1-12.	0.1	3
476	Hair Transplantation Surgery Versus Other Modalities of Treatment in Androgenetic Alopecia: A Narrative Review. Cosmetics, 2021, 8, 25.	1.5	5
477	ANDROGENETİK ALOPESİ. UludaÄŸ Üniversitesi Tıp FakÃ⅓ltesi Dergisi, 0, , .	0.2	0
478	Harnessing Drug Repurposing for Exploration of New Diseases: An Insight to Strategies and Case Studies. Current Molecular Medicine, 2021, 21, 111-132.	0.6	5
479	Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target. Journal of Medicinal Chemistry, 2021, 64, 4553-4566.	2.9	14
480	Evaluation of efficacy of intradermal injection therapy vs derma roller application for administration of QR678 Neo ® hair regrowth formulation for the treatment of Androgenetic Alopeciaâ€"A prospective study. Journal of Cosmetic Dermatology, 2021, 20, 3299-3307.	0.8	6
481	The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study. Aesthetic Surgery Journal, 2021, 41, NP1659-NP1672.	0.9	8
482	Indole Glycosides from <i>Calanthe discolor</i> with Proliferative Activity on Human Hair Follicle Dermal Papilla Cells. Chemical and Pharmaceutical Bulletin, 2021, 69, 464-471.	0.6	3
483	Beat-to-beat and spectral analyses of the noninvasive radial pulse and laser-Doppler signals in patients with hypertension. Clinical Hemorheology and Microcirculation, 2021, 79, 365-379.	0.9	5
484	Sulforaphane, L-Menthol, and Dexpanthenol as a Novel Active Cosmetic Ingredient Composition for Relieving Hair Loss Symptoms. Cosmetics, 2021, 8, 63.	1.5	3
485	Allopregnanolone: An overview on its synthesis and effects. Journal of Neuroendocrinology, 2022, 34, e12996.	1.2	33
486	Combination Approaches for Combatting Hair Loss. Dermatologic Clinics, 2021, 39, 479-485.	1.0	1
487	Ginseng in Hair Growth and Viability. , 0, , .		0
488	IMPROVEMENT OF ALOPECIA AND DECREASES IN HAIR CORTISOL AND DIHYDROTESTOSTERONE CONCENTRATIONS AFTER THE TOPICAL USE OF PLANT EXTRACTS IN MEN WITH ANDROGENETIC ALOPECIA. Asian Journal of Pharmaceutical and Clinical Research, 0, , 71-79.	0.3	1
489	Finasteride for hair loss: a review. Journal of Dermatological Treatment, 2022, 33, 1938-1946.	1.1	17
490	Hair growth-promotion effects at the cellular level and antioxidant activity of the plant-based extract Phyllotexâ,,¢. Heliyon, 2021, 7, e07888.	1.4	7
491	The role of benign prostatic hyperplasia treatments in ejaculatory dysfunction. Fertility and Sterility, 2021, 116, 611-617.	0.5	12
492	Hair transplantation: Basic overview. Journal of the American Academy of Dermatology, 2021, 85, 803-814.	0.6	41

#	Article	IF	Citations
493	Ent-kaurane-type diterpenoids from Isodonis Herba activate human hair follicle dermal papilla cells proliferation via the Akt/GSK-3β/β-catenin transduction pathway. Journal of Natural Medicines, 2021, 75, 326-338.	1.1	7
494	Finasteride, 1 mg (Propecia), Is the Optimal Dose for the Treatment of Men With Male Pattern Hair Loss. Archives of Dermatology, 1999, 135, 989-990.	1.7	18
495	Finasteride in a 1-mg Dose Is Safe and Effective. Archives of Dermatology, 1999, 135, 990-990.	1.7	5
496	Unilateral Gynecomastia Induced by Treatment With 1 mg of Oral Finasteride. Archives of Dermatology, 2002, 138, 543-544.	1.7	37
497	The Endocrine Control of the Hair Follicle. , 2008, , 23-39.		3
498	Male Androgenetic Alopecia. , 2008, , 159-170.		13
499	Molecular Basis of Androgenetic Alopecia. , 2010, , 9-24.		11
500	Hair Restoration., 2013, , 517-538.		2
501	Diseases of Hair., 2000, , 1099-1140.		3
503	Hair Restoration. , 2010, , 373-389.		1
504	Disorders of Hair and Nails. , 2016, , 136-174.e9.		2
505	Hair transplantation., 2009,, 187-232.		3
506	Current advances in stem cell-based therapies for hair regeneration. European Journal of Pharmacology, 2020, 881, 173197.	1.7	36
507	Post-finasteride syndrome: a surmountable challenge for clinicians. Fertility and Sterility, 2020, 113, 21-50.	0.5	57
508	Hair research and the newest micrograft techniques. Prime, 2011, 1, 44-57.	0.0	1
509	QR678 & QR678 Neo Hair Growth Formulations. Plastic and Reconstructive Surgery - Global Open, 2020, Publish Ahead of Print, e2843.	0.3	7
510	Hair Care Products. , 2005, , 129-167.		6
511	ANTIANDROGENS., 2002,, 32-40.		1

#	Article	IF	CITATIONS
513	Medicinal Herbal Complex Extract with Potential for Hair Growth-Promoting Activity. Journal of the Society of Cosmetic Scientists of Korea, 2012, 38, 277-287.	0.2	5
514	Pharmacologic interventions in aging hair. Clinical Interventions in Aging, 2006, 1, 121-129.	1.3	80
515	Propylene glycol free 5% minoxidil lotion formulation: cosmetic acceptability, local tolerability, clinical efficacy and in-vitro skin absorption evaluations. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 341-345.	0.8	6
517	Androgenetic Alopecia. Basic and Clinical Dermatology, 2008, , 107-118.	0.1	1
518	Medical Treatments for Male and Female Pattern Hair Loss. Series in Cosmetic and Laser Therapy, 2010, , 91-105.	0.0	3
519	Hair loss: diagnosis and management Cleveland Clinic Journal of Medicine, 2003, 70, 705-706.	0.6	7
520	Hair-Loss Preventing Effect of Grateloupia elliptica. Biomolecules and Therapeutics, 2012, 20, 118-124.	1.1	18
521	Efficacy of finasteride for treating patients with androgenetic alopecia who are pileous in other areas: A pilot study in Japan. Indian Journal of Dermatology, 2014, 59, 163.	0.1	7
522	A marine protein-based dietary supplement for subclinical hair thinning/loss: Results of a multisite, double-blind, placebo-controlled clinical trial. International Journal of Trichology, 2015, 7, 156.	0.1	25
523	A comment on the post-finasteride syndrome. International Journal of Trichology, 2018, 10, 255.	0.1	13
524	Adverse effects with finasteride 5 mg/day for patterned hair loss in premenopausal women. International Journal of Trichology, 2018, 10, 48.	0.1	10
525	The effect of GGC and CAG repeat polymorphisms on the androgen receptor gene in response to finasteride therapy in men with androgenetic alopecia. Journal of Research in Medical Sciences, 2019, 24, 104.	0.4	2
526	RE-ORGA, a Korean Herb Extract, Can Prevent Hair Loss Induced by Dihydrotestosterone in Human Dermal Papilla Cells. Annals of Dermatology, 2019, 31, 530.	0.3	4
527	The changing landscape of managing hair loss: a 30â€year perspective. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2123-2124.	1.3	0
528	Effect of Topical Grape Sap on Apoptosis in Hair Follicle Among Male Rats. Gene, Cell and Tissue, 2021, 9, .	0.2	1
529	Hair: Scalp Hair Growth Evaluation Methods. , 2000, , 241-254.		0
530	Störungen im Bereich der Androgenzielorgane. , 2000, , 247-265.		1
531	Systemische Therapie der androgenetischen Alopezie des Mannes. , 2000, , 432-433.		0

#	Article	IF	CITATIONS
532	Should Men Still Go Bald Gracefully?. International Society of Hair Restoration Surgery, 2000, 10, 109-116.	0.1	0
533	皮膚ä•af>af«af¢af³ç¶šç∵(1) a€"æ¬æ^é•a•af>af«af¢af³a€". Nishinihon Journal of Dermatology, 2001, 63, 43	8 4.4 2.	0
534	Disorders of Androgen Target Organs. , 2001, , 223-240.		1
535	皮膚ã•ãf>ãf«ãf¢ãf³ç¶šç∵(2) â€"æ¬æ^é•∙ã•ãf>ãf«ãf¢ãf³(ç¶š)—. Nishinihon Journal of Dermatology, 2001, 6	3, &6 1-55	6.0
536	Therapie der Alopezien. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2001, , 233-239.	0.0	0
537	Update in Dermatology. Annals of Internal Medicine, 2001, 135, 124.	2.0	0
538	HÃ g fige Haarkrankheiten. , 2002, , 1395-1422.		0
540	Androgens and Androgen Receptor in Dermatology. , 2002, , 411-476.		0
541	Trichologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2003, , 588-595.	0.0	0
542	Dihydrotestosterone and 5α-Reductase. , 2003, , 77-88.		0
543	Spezielle Indikationen zur kosmetischen Behandlung. , 2004, , 289-349.		0
544	Gender Differences in Dermatology. , 2004, , 1241-1245.		0
545	Therapie der androgenetischen Alopezie bei MĤnern und Frauen. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 297-301.	0.0	0
546	Trilostane Treatment of Canine Alopecia X in an American Pit Bull Terrier. Acta Veterinaria Brno, 2007, 76, 113-120.	0.2	0
547	Haare: Mal zu viel, mal zu wenig. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2007, , 108-116.	0.0	0
548	Androgenetic Alopecia. , 2008, , 123-134.		0
549	Common Hair Problems: Dandruff and Androgenetic Alopecia. , 2009, , 61-71.		0
550	Inflammatory Phenomena and Fibrosis in Androgenetic Alopecia. , 2010, , 25-32.		1

#	Article	IF	CITATIONS
551	Possibilities and Limitations for Reversal of Age-Related Hair Loss., 2010, , 193-205.		1
552	The Use of Herbal Medicine. , 2010, , 70-71.		1
553	Hair Disorders. , 2010, , 289-293.e1.		1
554	Hair Growth. , 2011, , 227-245.		O
555	Planning and Organization. Series in Cosmetic and Laser Therapy, 2010, , 106-197.	0.0	3
556	Disorders of Hair and Nails. , 2011, , 130-166.		2
557	Alopecias. , 2011, , 369-378.		0
558	Hair Transplantation. , 2012, , 129-167.		0
559	Hair loss and hair transplantation. Series in Cosmetic and Laser Therapy, 2011, , 121-130.	0.0	0
560	Notes from the Editor Emeritus: Medical therapy for hair loss: what we know and what we need to find out. International Society of Hair Restoration Surgery, 2013, 23, 5-6.	0.1	0
561	Cell Biology and Disease of Hair Follicle (2). Nishinihon Journal of Dermatology, 2013, 75, 448-453.	0.0	0
562	Diagnosis and Treatment. , 2014, , 75-215.		0
566	Rebuilding Trust: Novel Standards for Reporting the Effectiveness of Male-Pattern Hair Loss Treatment. Biometrics & Biostatistics International Journal, 2016, 4, .	0.2	0
567	Inflammatory Disorders of the Cutaneous Appendages. , 2017, , 209-233.		0
568	Clinical Assessment of the Scalp and Hair. , 2017, , 757-760.		0
569	Alopecias and Disorders of the Hair Follicle. , 2017, , 331-357.		0
570	MICRONEEDLING WITH PLATELET-RICH PLASMA VERSUS MICRONEEDLING WITH TOPICAL 5% MINOXIDIL IN PATIENTS WITH ANDROGENETIC ALOPECIA- A COMPARATIVE STUDY. Journal of Evolution of Medical and Dental Sciences, 2017, 6, 2182-2186.	0.1	1
571	Investigation of Antioxidant Activity of Cynanchi Wilfordii Radix and Inhibitory Effect of 5α-reductase mRNA in Human Dermal Papilla Cells. Journal of Physiology & Pathology in Korean Medicine, 2017, 31, 374-379.	0.2	0

#	Article	IF	CITATIONS
572	Application of Ostrich Antibodies to the Restoration of Hair Growth, a Preliminary and Case Report. Journal of Cosmetics Dermatological Sciences and Applications, 2018, 08, 179-184.	0.1	1
573	Effect of Polarized Light Therapy on Hair Regrowth in Alopecia Areata. Medical Journal of the University of Cairo Faculty of Medicine, 2018, 86, 2959-2965.	0.0	0
574	Melandrium firmumExtract Promotes Hair Growth by Modulating 5α-Reductase Activity and Gene Expression in C57BL/6J Mice. Annals of Dermatology, 2019, 31, 502.	0.3	2
575	The Efficacy of Ostrich Antibodies to Dihydrotestosterone and 5 <i>α</i> -Reductase in the Restoration of Hair Growth. Health, 2019, 11, 1320-1330.	0.1	0
576	Finasteride for Androgenetic Alopecia Is Not Associated with Sexual Dysfunction: A Survey-Based, Single-Centre, Controlled Study. International Society of Hair Restoration Surgery, 2019, 29, 89-96.	0.1	0
577	Androgenetic Alopecia: Clinical Treatment. , 2020, , 91-108.		2
578	The Role of Finasteride in the Management of Androgenetic Alopecia in Male: A Narrative Review. Indian Journal of Pharmacy Practice, 2019, 13, 03-13.	0.1	2
579	Hair., 2020,, 239-258.		0
580	Hair Follicle Stem Cells and Hair Regeneration. , 2020, , 265-296.		1
581	Influence of Human Placenta Extracts on Prostanoids Production in Cultured Hair Follicle-Derived Keratinocytes: The Possibility of Pharmaceutical Regenerative Medicine. Journal of St Marianna University, 2020, 11, 21-29.	0.1	0
582	Hair Follicle Stem Cells and Hair Regeneration. , 2020, , 1-32.		0
583	Safety and Efficacy of Nutrition-Based Interventions for Hair. , 2020, , 257-288.		0
584	Medical Treatments for Androgenetic Alopecia. , 2020, , 9-28.		0
585	Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women. Bioscience Reports, 2020, 40, .	1.1	2
586	Haut und Haare: Die dermatologische Perspektive. , 2006, , 95-112.		0
587	Die Haarsprechstunde als neues IGeL-Konzept — Inhaltliche und strukturelle Grundlagen. , 2005, , 363-376.		0
588	Effluvien., 0,, 339-353.		0
589	Endokrinologische Aspekte der Hautalterung. , 2008, , 37-57.		0

#	Article	IF	CITATIONS
590	Direct-to-consumer advertising. Finasteride for male pattern hair loss. Canadian Family Physician, 2001, 47, 1751-5.	0.1	1
591	Female pattern hair loss: current treatment concepts. Clinical Interventions in Aging, 2007, 2, 189-99.	1.3	119
592	Review of factors affecting the growth and survival of follicular grafts. Journal of Cutaneous and Aesthetic Surgery, 2010, 3, 69-75.	0.2	35
593	Persistent sexual dysfunction and depression in finasteride users for male pattern hair loss: a serious concern or red herring?. Journal of Clinical and Aesthetic Dermatology, 2014, 7, 51-5.	0.1	21
594	Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review. Journal of Clinical and Aesthetic Dermatology, 2016, 9, 56-62.	0.1	68
595	Androgenetic Alopecia Treatment in Asian Men. Journal of Clinical and Aesthetic Dermatology, 2018, 11, 32-35.	0.1	6
596	Stromal Vascular Fraction and its Role in the Management of Alopecia: A Review. Journal of Clinical and Aesthetic Dermatology, 2019, 12, 35-44.	0.1	4
597	An Herbal Extract Combination (Biochanin A, Acetyl tetrapeptide-3, and Ginseng Extracts) versus 3% Minoxidil Solution for the Treatment of Androgenetic Alopecia: A 24-week, Prospective, Randomized, Triple-blind, Controlled Trial. Journal of Clinical and Aesthetic Dermatology, 2020, 13, 32-37.	0.1	8
598	Comparative clinical assessment of 5% minoxidil topical application with supplemental intradermal meso-solution administration for the management of androgenetic alopecia in men. Indian Journal of Drugs in Dermatology, 2021, 7, 67.	0.0	0
600	How to Deal with the Issues of Fertility, Malignancies, and the Postfinasteride Syndrome while Prescribing Finasteride for Male Pattern Hair Loss. Skin Appendage Disorders, 0, , 1-4.	0.5	0
601	TOPICAL DELIVERY OF DRUGS USING ETHOSOMES: A REVIEW. Indian Drugs, 2019, 56, 7-20.	0.1	6
602	Haut und Haare. , 2021, , 187-194.		0
603	Understanding Pattern Hair Loss—Hair Biology Impacted by Genes, Androgens, Prostaglandins and Epigenetic Factors. Indian Journal of Plastic Surgery, 2021, 54, 385-392.	0.2	5
604	Advances in hair growth. Faculty Reviews, 2022, 11, 1.	1.7	15
605	Evaluation of the safety and effectiveness of intradermal administration of QR678 Neo ® hair growth factor formulation: A phaseâ€IV, openâ€Iabel, singleâ€arm multiâ€ethnicity clinical trial. Journal of Cosmetic Dermatology, 2022, 21, 580-589.	0.8	2
606	Hormonal and Genetic Etiology of Male Androgenetic Alopecia. , 2022, , 135-180.		2
608	Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis. Asian Journal of Andrology, 2022, 24, 390.	0.8	2
609	Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients. JAMA Dermatology, 2022, 158, 266.	2.0	35

#	Article	IF	CITATIONS
610	Review of factors affecting the growth and survival of follicular grafts. Journal of Cutaneous and Aesthetic Surgery, 2010, 3, 69.	0.2	19
611	5-Bromo-3,4-dihydroxybenzaldehyde Promotes Hair Growth through Activation of Wnt/β-Catenin and Autophagy Pathways and Inhibition of TGF-β Pathways in Dermal Papilla Cells. Molecules, 2022, 27, 2176.	1.7	9
612	Combination of Plateletâ€Rich Plasma and Platelet Gel in Treatment of Resistance Androgenic Alopecia: a Case Series Study. Journal of Cosmetic Dermatology, 2022, , .	0.8	3
613	Modulation of Hair Growth Promoting Effect by Natural Products. Pharmaceutics, 2021, 13, 2163.	2.0	15
614	A Systematic Review and Meta-analysis of Randomized Controlled Trials of United States Food and Drug Administration-Approved, Home-use, Low-Level Light/Laser Therapy Devices for Pattern Hair Loss: Device Design and Technology Journal of Clinical and Aesthetic Dermatology, 2021, 14, E64-E75.	0.1	0
615	Systemic therapy of androgenic alopecia. Vestnik Dermatologii I Venerologii, 2015, 91, 41-45.	0.2	O
616	A comparative study of efficacy of 5% minoxidil and 5% minoxidil plus platelet-rich plasma in same patient for treatment of androgenetic alopecia. Journal of Cutaneous and Aesthetic Surgery, 2022, 15, 71.	0.2	5
617	Effects of some medicinal plant extracts on dermal papilla cells. Journal of Cosmetic Dermatology, 2022, 21, 6109-6117.	0.8	2
618	A Comprehensive Review of Natural Alternatives for Treatment of Alopecia with an Overview of Market Products. Journal of Medicinal Food, 0, , .	0.8	0
619	Long-Term (Over 10 Years) Evaluation of Efficacy and Safety of Finasteride in Japanese Men with Androgenetic Alopecia: Summary of Three Investigations. International Society of Hair Restoration Surgery, 2022, 32, 130-132.	0.1	0
620	Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. Journal of Dermatological Treatment, 2022, 33, 2946-2962.	1.1	23
621	Prospects of integrated multi-omics-driven biomarkers for efficient hair loss therapy from systems biology perspective. Gene Reports, 2022, 28, 101657.	0.4	0
622	Hair Growth Booster Effects of Micro-Needling with Low-Level Led Therapy and Growth Factors on Subjects Treated with Finasteride®. Applied Sciences (Switzerland), 2022, 12, 9164.	1.3	2
623	Human activity-driven self-powered hair follicle stimulation system. Nano Energy, 2022, 103, 107772.	8.2	4
624	Human Activity-Driven Self-Powered Hair Follicle Stimulation System. SSRN Electronic Journal, 0, , .	0.4	0
625	Pendekatan Diagnosis dan Tata Laksana Alopesia Androgenetik., 2022, 35, 3-9.		0
626	Evaluation of choice of medicine for hair growth in practising hair implant surgeons- original research. International Journal of Health Sciences, 0, , 2621-2627.	0.0	0
627	Improvement of Hair Loss by a Persimmon Leaf, Green Tea, and Sophora Fruit Extract Complex (BLH308). Korean Journal of Medicinal Crop Science, 2022, 30, 247-263.	0.1	2

#	Article	IF	Citations
628	Rosemary (Rosmarinus Officinalis). , 2022, , 495-499.		0
629	Marine Extract Compounds. , 2022, , 239-246.		O
630	Proanthocyanidins. , 2022, , 445-449.		0
631	Finasteride. , 2022, , 41-75.		O
633	Gut Inflammation Induced by Finasteride Withdrawal: Therapeutic Effect of Allopregnanolone in Adult Male Rats. Biomolecules, 2022, 12, 1567.	1.8	4
634	Dutasteride nanoemulsion preparation to inhibit 5â€alphaâ€hair follicle reductase enzymes in the hair follicle; an ex vivo study. IET Nanobiotechnology, 2023, 17, 13-21.	1.9	5
635	The Interplay between Finasteride-Induced Androgen Imbalance, Endoplasmic Reticulum Stress, Oxidative Stress, and Liver Disorders in Paternal and Filial Generation. Biomedicines, 2022, 10, 2725.	1.4	2
636	An assessment for measuring loneliness, anxiety, and depression in male patients with androgenetic alopecia undergoing hair transplantation surgery: A beforeâ€after study. Journal of Cosmetic Dermatology, 2022, 21, 7013-7017.	0.8	0
637	Digital health platforms expand access and improve care for male androgenetic alopecia. International Journal of Dermatology, 2023, 62, 217-220.	0.5	5
638	Atualizações sobre o tratamento da alopécia androgenética em homens. Brazilian Journal of Health Review, 2022, 5, 22376-22392.	0.0	O
639	Evaluation of the efficacy and safety of topical procyanidin b2 and placebo in the treatment of androgenetic alopecia in men; A randomized, double-blind, placebo-controlled study. Turk Dermatoloji Dergisi, 2022, 16, 108.	0.3	1
640	Limonin, a Component of Immature Citrus Fruits, Activates Anagen Signaling in Dermal Papilla Cells. Nutrients, 2022, 14, 5358.	1.7	3
641	Anabolic–androgenic steroids: How do they work and what are the risks?. Frontiers in Endocrinology, 0, 13, .	1.5	27
642	Finasteride for Androgenetic Alopecia Is Not Associated with Sexual Dysfunction: A Survey-Based, Single-Centre, Controlled Study. International Society of Hair Restoration Surgery, 2022, 32, 209-212.	0.1	0
643	Clinical Assessment of the Scalp and Hair. , 2015, , 1-4.		0
644	Stauntonia hexaphylla Extract Ameliorates Androgenic Alopecia by Inhibiting Androgen Signaling in Testosterone-induced Alopecia Mice. Iranian Journal of Pharmaceutical Research, 2023, 21, .	0.3	0
645	Integrative and Mechanistic Approach to the Hair Growth Cycle and Hair Loss. Journal of Clinical Medicine, 2023, 12, 893.	1.0	14
646	A microfluidic application for mass production of drug-loaded polymeric microspheres for a long-acting injectable with IVL-DrugFluidic \hat{A}^{0} , a novel microfluidic microsphere manufacturing platform technology. OpenNano, 2023, 12, 100153.	1.8	1

#	Article	IF	CITATIONS
647	Methods of hair restoration for men and women. Journal of Aesthetic Nursing, 2023, 12, 19-23.	0.0	0
648	Reducing Surgical Risks for Hair Replacement Surgery. Facial Plastic Surgery Clinics of North America, 2023, 31, 263-274.	0.9	0
649	Therapeutic Potentiality of Celtis choseniana Nakai on Androgenic Alopecia through Repression of Androgen Action and Modulation of Wnt∫î²-catenin Signaling. Natural Product Sciences, 2023, 29, 31-41.	0.2	0
650	Mechanistic synergy of hair growth promotion by the Avicennia marina extract and its active constituent (avicequinone C) in dermal papilla cells isolated from androgenic alopecia patients. PLoS ONE, 2023, 18, e0284853.	1.1	3
655	Minoxidil, finasteride, and dutasteride. , 2024, , 93-105.		0
660	The post-finasteride syndrome: possible etiological mechanisms and symptoms. International Journal of Impotence Research, 0, , .	1.0	1
661	From target discovery to clinical drug development with human genetics. Nature, 2023, 620, 737-745.	13.7	14
665	Skin Androgen-Related Disorders: Hormonal Treatment. , 2023, , 1661-1678.		0